PMA device
Restylane Injectable Gel
Q-Med AB · Implant, Dermal, For Aesthetic Use (LMH, Class III) · First FDA decision Dec 12, 2003, newest Dec 20, 2022Aesthetic skin, fat and body contouring
Last checked: Nov 20, 2026Source: FDA, CMS, ClinicalTrials.gov, PubMed
FDA decisions
8
PMA pathway
Device trials
32
Naming "Restylane Injectable Gel"
MAUDE reports
1
Brand "Restylane Injectable Gel", since 2015
PubMed studies
3
Mentioning "Restylane Injectable Gel"
AI summary across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, MAUDE and PubMed data on this page, plus web searches for payment facts.
Product review deck
A slide deck reviewing Restylane Injectable Gel
About ten slides on the technology, clinical evidence, regulatory history and commercialization, built with AI from the data on this page and web research, with sources. Download it as PowerPoint to edit or as PDF to share.
- Executive summary and key facts
- Technology, with pictures of the device
- Clinical evidence and trials
- Regulatory history and safety
- Reimbursement, market and competition
- Risks, outlook and sources
AI-written from public data and may contain mistakes. Check each fact against its source before relying on it. Not investment, legal, reimbursement or medical advice.
FDA decisions
The newest 6 of 8 decisions filed under this name.
- Restylane Injectable GelPMA supplement
P040024-S132 · Decided Dec 20, 2022 · 105 days after receipt · Normal 180 Day Track
Device type: Implant, dermal, for aesthetic use (LMH) · General & Plastic Surgery
5 more FDA decisions with a free account
Medicare coverage
National and local coverage documents whose titles match this device or its device type. Payment add-ons (NTAP, pass-through, TCET) and likely codes are covered in the summary above.
No Medicare coverage document has a title matching this device or device type. Many devices are paid under existing codes without one.
Clinical trials
Device studies on ClinicalTrials.gov that name "Restylane Injectable Gel", any status and sponsor, newest update first.
- A Study to Evaluate the Effectiveness and Safety of Restylane Shaype in the Improvement of Jawline DefinitionPivotal-lookingRecruiting
Galderma R&DNot on our public-company list
NCT07805512 · 162 participants (planned) · Start Sep 28, 2026 · Primary completion Sep 2027
Device: Restylane Shaype · For: Jawline Definition
Sites: Beijing, China; Nanjing, China; Chengdu, China · 6 sites in all
31 more trials with a free account
Adverse event reports (MAUDE)
Reports received since 2015 naming the brand "Restylane Injectable Gel", and for the whole product code for context.
This brand
1 reports: 0 malfunction, 1 injury, 0 death
Whole product code LMH
16,542 reports: 1,388 malfunction, 15,105 injury, 12 death
Newest reports for this brand
MW5167475 · Received Mar 11, 2025 · Event dated Feb 14, 2024
Device type: Implant, Dermal, For Aesthetic Use (LMH)
Patient problem as coded: Erythema; Inflammation; Scar Tissue; Rupture; Deformity/ Disfigurement; Skin Burning Sensation
Recalls
From FDA's recall database. FDA lists each recalled product separately, so one recall can appear several times. A recall is often a correction or a labeling change, not a removal from the market.
No recall in FDA's data is linked to these FDA numbers.
Published research
The most relevant PubMed records for "Restylane Injectable Gel"[tiab]. The summary above synthesizes these.
- Safety and Effectiveness of Hyaluronic Acid Injectable Gel in Correcting Moderate Nasolabial Folds in Chinese Subjects.
Wu Y, Xu J, Jia Y, et al. · J Drugs Dermatol · 2016Multicenter Study, Randomized Controlled Trial
- Safety and Effectiveness of Juvéderm Ultra Plus Injectable Gel in Correcting Severe Nasolabial Folds in Chinese Subjects.
Li D, Xie Y, Li Q, et al. · Plast Reconstr Surg Glob Open · 2017
- An open-label, pilot study to assess the effectiveness and safety of hyaluronic acid gel in the restoration of soft tissue fullness of the lips.
Solish N, Swift A · J Drugs Dermatol · 2011Clinical Trial, Multicenter Study
Other devices of this type
Also filed under product code LMH.
- RADIESSE® Injectable ImplantMerz North America, Inc. · PMA 2026
- SculptraQ-Med AB · PMA 2024
- Belotero Balance Dermal FillerMerz North America, Inc. · PMA 2026
- Restylane® ContourQ-Med AB · PMA 2026
- Juvederm Voluma XCAllergan · PMA 2025
- Juvéderm Voluma XC, Vollure XC, Volbella XC, Volux XC, SkinviveAllergan · PMA 2026
- Restylane® Lyft with LidocaineQ-Med AB · PMA 2025
- Belotero Balance (+) Lidocaine Dermal FillerMerz North America, Inc. · PMA 2025
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.